Tango Therapeutics, Inc.

Tango Therapeutics, Inc. filed an 8-K current report with the Securities and Exchange Commission on June 6, 2025, the latest regulatory disclosure from the oncology-focused biopharmaceutical company that entered public markets through BCTG Acquisition Corp. BCTG priced its initial public offering in 2020 and was sponsored by BCTG LLC, an entity affiliated with Boxer Capital and TC BioInnovations, with a stated focus on the biotechnology and life sciences sector. The SPAC completed its business combination with Tango Therapeutics, a precision cancer medicine company utilizing CRISPR-based functional genomics, in 2021, after which the combined entity began trading on Nasdaq. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics across the entire SPAC universe.